Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001477932-13-005936
Filing Date
2013-12-04
Accepted
2013-12-04 14:24:07
Documents
9
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q vnsn_10q.htm 10-Q 797592
2 CERTIFICATION vnsn_ex311.htm EX-31.1 17866
3 CERTIFICATION vnsn_ex321.htm EX-32.1 8591
  Complete submission text file 0001477932-13-005936.txt   3598133

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT vnsn-20130930.xml EX-101.INS 414741
5 XBRL TAXONOMY EXTENSION SCHEMA vnsn-20130930.xsd EX-101.SCH 44832
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnsn-20130930_cal.xml EX-101.CAL 53028
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnsn-20130930_def.xml EX-101.DEF 67085
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnsn-20130930_lab.xml EX-101.LAB 205719
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnsn-20130930_pre.xml EX-101.PRE 161615
Mailing Address 101 CONVENTION CENTRE DRIVE, SUITE 700 LAS VEGAS NV 89109
Business Address 101 CONVENTION CENTRE DRIVE, SUITE 700 LAS VEGAS NV 89109 775-636-6986
Vansen Pharma Inc. (Filer) CIK: 0001378076 (see all company filings)

EIN.: 202881151 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33715 | Film No.: 131256824
SIC: 1040 Gold and Silver Ores